Liu Zuo-jin, Li Sheng-wei, Li Xu-hong, Peng Yong, You Hai-bo, Li Shou-bai, Gong Jian-ping
Department of Hepatobiliary Surgery, the Second Clinical College, Chongqing University of Medical Sciences, Chongqing 400010, China.
Sichuan Da Xue Xue Bao Yi Xue Ban. 2006 Sep;37(5):679-82.
To explore the feasibility of interleukin 1 receptor associated kinase-4 (IRAK-4) as gene therapy target for liver ischemia/reperfusion injury (I/RI) and effective approach in vivo for short hairpin RNA (shRNA) interference used to gene therapy in liver graft hqappened.
Sprague-Dawley rats were randomly divided into three groups: the control group, the in vivo transfection group (IVT) and the cold ischemia transfection group (CIT). Experiments of orthotopic liver transplantation were performed by two-cuff method. CIT were perfused with IRAK-4-shRNA plasmid (pSIIRAK-4) during cold ischemia phase, IVT received the equivalent volumes (2 mL) of pSIIRAK-4 after portal vein inosculated, and the control group leaved without any treatment. At 0 min, 60 min and 180 min after reperfusion, the expression of IRAK-4 gene and protein level were determined by RT-PCR and Western blot. The serum TNF-alpha level was detected by ELISA. Liver histopathological changes and cell apoptosis were observed by electron microscope and TUNEL.
After reperfusion, the expression of IRAK-4 were largely depressed in CIT than that of IVT and the control group (P < 0.01), and furthermore, the serum TNF-alpha level, proportion of hepatocyte apoptosis and severity of hepatocyte injury were also lower than the latter.
These results indicate that depression IRAK-4 expression with IRAK-4-shRNA through portal vein perfusion during cold ischemia phase could effectively blunt graft hepatic I/RI.
探讨白细胞介素1受体相关激酶4(IRAK-4)作为肝缺血/再灌注损伤(I/RI)基因治疗靶点的可行性以及短发夹RNA(shRNA)干扰在肝移植中进行基因治疗的有效体内方法。
将Sprague-Dawley大鼠随机分为三组:对照组、体内转染组(IVT)和冷缺血转染组(CIT)。采用双袖套法进行原位肝移植实验。CIT在冷缺血期用IRAK-4-shRNA质粒(pSIIRAK-4)灌注,IVT在门静脉吻合后接受等量(2 mL)的pSIIRAK-4,对照组不做任何处理。再灌注后0分钟、60分钟和180分钟,通过RT-PCR和Western blot检测IRAK-4基因表达和蛋白水平。用ELISA检测血清肿瘤坏死因子-α(TNF-α)水平。通过电子显微镜和TUNEL观察肝组织病理学变化和细胞凋亡情况。
再灌注后,CIT组IRAK-4的表达明显低于IVT组和对照组(P < 0.01),此外,血清TNF-α水平、肝细胞凋亡比例和肝细胞损伤严重程度也低于后两者。
这些结果表明,在冷缺血期通过门静脉灌注IRAK-4-shRNA抑制IRAK-4表达可有效减轻移植肝I/RI。